Abstract:Objective　To analyze the evolution of rtI233V mutation in the reverse transcriptase domain of hepatitis B virus (HBV) and its association with adefovir dipivoxil (ADV) resistance. Methods　The rate of detection of rtI233V mutation in 9830 patients with chronic HBV infection was analyzed. HBV reverse transcriptase genes isolated from serial serum samples of two patients were amplified by nested PCR, and clonal sequencing (>20 clones/sample) was performed to analyze the evolution of rtI233V mutations. The replica of pTriEx-HBV1.1 vectors harboring wild-type and mutant strains (rtI233V, rtN236T, rtI233V+rtN236T) were respectively constructed and transiently transfected into HepG2 cells. Media containing serial concentrations of lamivudine (LAM), ADV, entecavir (ETV), or tenofovir (TDF) were used to treat the cells. Then HBV DNA in the supernatants was quantitatively determined by real-time PCR in order to analyze HBV mutants' replication competence and phenotypic characteristics under the drug pressures. Results　The detection rate of rtI233V mutation in 9830 nucleos(t)ide analogues-treated patients was 0.28% (28/9830), including 0.19% (19 patients) with rtI233V individual mutation and 0.09% (9 patients) with rtI233V mutation combining with rtN236T or other mutations. All of the patients had rtI233V had ADV exposure history: 16 (57.1%) of them received ADV monotherapy for over six months, and 12(42.9%) of them received ADV combined sequential therapy for over 12 months. Replication competence and phenotypic resistance analysis showed rtI233V and wild-type strains had similar viral replication competence, while rtN236T exhibited significantly lower replication competence compared with wild-type strains. rtI233V strains remained sensitive to LAM, ADV, ETV, and TDF and showed little influence on drug resistance when combined with rtN236T, but it showed ability to restore the defected replication capacity of rtN236T strains. Conclusions　 The rtI233V mutation is associated with sub-optimal response to ADV. Though it does not directly reduce virus sensitivity to ADV, rtI233V mutation enhances replication competence of ADV resistant strains, and it is a complementary mutation. DOI: 10.11855/j.issn.0577-7402.2015.03.04

Hepatitis B Virus Genotype C Encoding Resistance Mutations That Emerge During Adefovir Dipivoxil Therapy: in Vitro Replication Phenotype

Rte218g, a Novel Hepatitis B Virus Mutation with Resistance to Adefovir Dipivoxil in Patients with Chronic Hepatitis B

The Rta181s Mutation of Hepatitis B Virus Primarily Confers Resistance to Adefovir Dipivoxil

[Comparison of Antiviral Responses to Adefovir Dipivoxil Therapy of Genotype B and Genotype C HBV Infected Patients].

Hepatitis B Virus Genotype-Associated Variability in Antiviral Response to Adefovir Dipivoxil Therapy in Chinese Han Population.

Effect of Hepatitis B Virus Genotypes on the Efficacy of Adefovir Dipivoxil Antiviral Therapy

The Relationship Between Resistance Mutants Induced by Adefovir(adv) and Hepatitis B Virus(hbv) Genotypes

Polymerase Mutations Rtn238r, Rtt240y and Rtn248h of Hepatitis B Virus Decrease Susceptibility to Adefovir

Dissection of Mechanism for the Adefovir Dipivoxil Resistance in Chronic Hepatitis B Patients

Hepatitis B Virus (HBV) Subgenotypes C2 and B2 Differ in Lamivudine- and Adefovir-Resistance-Associated Mutational Patterns in HBV-Infected Chinese Patients

Analysis for phenotypic resistant characteristics of a novel mutation rtN236V in the reverse-transcriptase domain of hepatitis B virus isolated from an adefovir dipivoxil-refractory patient with chronic hepatitis B

Screening and Identification of a Novel Adefovir Dipivoxil Resistance Associated Mutation, RTN236V, of HBV from a Large Cohort of HBV-Infected Patients

The relationship between HBV genotypes and antiviral efficacy of adefovir dipivoxil treatment

Efficacy of Adefovir Dipivoxil Was Not Related to Genotypes B and C of Hepatitis B Virus: A Randomized, Double-Blind, Multicenter Clinical Study

An antiviral drug-resistant mutant of hepatitis B virus with high replication capacity in association with a large in-frame deletion in the preS1 region of viral surface gene

Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C

Deep Sequencing Analysis of HBV Genotype Shift and Correlation with Antiviral Efficiency During Adefovir Dipivoxil Therapy.

Analysis of evolution and virological characteristics of rtI233V mutations in the hepatitis B virus reverse transcriptase domain

Factors Influencing Inadequate or Suboptimal Response to Adefovir with or Without Genotypic Resistance.

Increased Occurrence of Mutant rtI233V of HBV in Patients Receiving Adefovir Therapy

Effect of hepatitis B virus subgenotype on antiviral response in nucleoside-treated hepatitis B envelope antigen-positive patients.